Literature DB >> 28659336

Ibrutinib may impair serological responses to influenza vaccination.

Abby P Douglas1,2, Jason A Trubiano1,2, Ian Barr3, Vivian Leung3, Monica A Slavin1,2, Constantine S Tam4,5,6.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28659336      PMCID： PMC5622870          DOI： 10.3324/haematol.2017.164285

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  14 in total

1.  Efficacy of the influenza vaccine in patients with malignant lymphoma.

Authors:  Joseph J Mazza; Steven H Yale; Jodi R Arrowood; Cory E Reynolds; Ingrid Glurich; Po-Huang Chyou; James G Linneman; Kurt D Reed
Journal:  Clin Med Res       Date:  2005-11

2.  Influenza virus vaccination and booster in B-cell chronic lymphocytic leukaemia patients.

Authors:  A M.T. van der Velden; A H.L. Mulder; A Hartkamp; R J.A. Diepersloot; H van Velzen-Blad; D H. Biesma
Journal:  Eur J Intern Med       Date:  2001-09       Impact factor: 4.487

3.  Seasonal Influenza Vaccination in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib.

Authors:  Clare Sun; Jin Gao; Laura Couzens; Xin Tian; Mohammed Z Farooqui; Maryna C Eichelberger; Adrian Wiestner
Journal:  JAMA Oncol       Date:  2016-12-01       Impact factor: 31.777

4.  Measuring T cell immunity to influenza vaccination in children after haemopoietic stem cell transplantation.

Authors:  W Nicholas Haining; John W Evans; Nilufer P Seth; G Derek Callaway; Kai W Wucherpfennig; Lee M Nadler; Eva C Guinan
Journal:  Br J Haematol       Date:  2004-11       Impact factor: 6.998

5.  Vaccination of patients with haematological malignancies with one or two doses of influenza vaccine: a randomised study.

Authors:  Per Ljungman; Hareth Nahi; Annika Linde
Journal:  Br J Haematol       Date:  2005-07       Impact factor: 6.998

6.  Influenza virus vaccine in B-cell chronic lymphocytic leukaemia patients.

Authors:  D A Gribabis; P Panayiotidis; V A Boussiotis; C Hannoun; G A Pangalis
Journal:  Acta Haematol       Date:  1994       Impact factor: 2.195

7.  2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.

Authors:  Lorry G Rubin; Myron J Levin; Per Ljungman; E Graham Davies; Robin Avery; Marcie Tomblyn; Athos Bousvaros; Shireesha Dhanireddy; Lillian Sung; Harry Keyserling; Insoo Kang
Journal:  Clin Infect Dis       Date:  2014-02       Impact factor: 9.079

8.  Partial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib.

Authors:  Clare Sun; Xin Tian; Yuh Shan Lee; Sreenivasulu Gunti; Andrew Lipsky; Sarah E M Herman; Dalia Salem; Maryalice Stetler-Stevenson; Constance Yuan; Lela Kardava; Susan Moir; Irina Maric; Janet Valdez; Susan Soto; Gerald E Marti; Mohammed Z Farooqui; Abner L Notkins; Adrian Wiestner; Georg Aue
Journal:  Blood       Date:  2015-09-03       Impact factor: 22.113

9.  Epidemiology of influenza A virus infection in patients with acute or chronic leukemia.

Authors:  L S Elting; E Whimbey; W Lo; R Couch; M Andreeff; G P Bodey
Journal:  Support Care Cancer       Date:  1995-05       Impact factor: 3.603

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  34 in total

1.  Response to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL).

Authors:  Francesca Romana Mauro; Diana Giannarelli; Clementina Maria Galluzzo; Candida Vitale; Andrea Visentin; Costantino Riemma; Serena Rosati; Marika Porrazzo; Sara Pepe; Marta Coscia; Livio Trentin; Massimo Gentile; Sara Raponi; Alessandra Micozzi; Giuseppe Gentile; Silvia Baroncelli
Journal:  Leukemia       Date:  2020-06-17       Impact factor: 11.528

2.  BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).

Authors:  Elise A Chong; Lindsey E Roeker; Mazyar Shadman; Matthew S Davids; Stephen J Schuster; Anthony R Mato
Journal:  Clin Cancer Res       Date:  2020-04-28       Impact factor: 12.531

Review 3.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 4.  Vaccination of the Stem Cell Transplant Recipient and the Hematologic Malignancy Patient.

Authors:  Mini Kamboj; Monika K Shah
Journal:  Infect Dis Clin North Am       Date:  2019-06       Impact factor: 5.982

Review 5.  An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations.

Authors:  Bulent Kantarcioglu; Omer Iqbal; Joseph Lewis; Charles A Carter; Meharvan Singh; Fabio Lievano; Mark Ligocki; Walter Jeske; Cafer Adiguzel; Grigoris T Gerotziafas; Jawed Fareed
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 2.389

6.  The humoral immune response to high-dose influenza vaccine in persons with monoclonal B-cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL).

Authors:  Jennifer A Whitaker; Sameer A Parikh; Tait D Shanafelt; Neil E Kay; Richard B Kennedy; Diane E Grill; Krista M Goergen; Timothy G Call; Saad S Kendarian; Wei Ding; Gregory A Poland
Journal:  Vaccine       Date:  2021-01-16       Impact factor: 3.641

7.  COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia.

Authors:  Lindsey E Roeker; David A Knorr; Meghan C Thompson; Mariely Nivar; Sonia Lebowitz; Nicole Peters; Isaac Deonarine; Saddia Momotaj; Saumya Sharan; Vanessa Chanlatte; Bianca Hampton; Liana Butala; Lindsay Amato; Angela Richford; Jessica Lunkenheimer; Kristen Battiato; Carissa Laudati; Anthony R Mato
Journal:  Leukemia       Date:  2021-05-13       Impact factor: 11.528

Review 8.  BTK Inhibitors in Chronic Lymphocytic Leukemia: Biological Activity and Immune Effects.

Authors:  Marzia Palma; Tom A Mulder; Anders Österborg
Journal:  Front Immunol       Date:  2021-07-01       Impact factor: 7.561

9.  A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.

Authors:  Lisa S Chen; Prithviraj Bose; Nichole D Cruz; Yongying Jiang; Qi Wu; Philip A Thompson; Shuju Feng; Michael H Kroll; Wei Qiao; Xuelin Huang; Nitin Jain; William G Wierda; Michael J Keating; Varsha Gandhi
Journal:  Blood       Date:  2018-09-25       Impact factor: 25.476

Review 10.  Can Immunocompetence Be Restored in Chronic Lymphocytic Leukemia?

Authors:  Clare Sun; Adrian Wiestner
Journal:  Hematol Oncol Clin North Am       Date:  2021-05-26       Impact factor: 2.861
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.